Apolipoprotein A-I Mimetic Peptides

Gordon, 1977, High density lipoprotein as a protective factor against coronary heart disease. The Framingham study., Am J Med, 62, 707, 10.1016/0002-9343(77)90874-9

Shah, 2007, High-density lipoprotein mimetics: focus on synthetic high-density lipoprotein., Am J Cardiol, 100, S62, 10.1016/j.amjcard.2007.09.081

Hausenloy, 2008, Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels., Heart, 94, 706, 10.1136/hrt.2007.125401

Gordon, 1989, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies., Circulation, 79, 8, 10.1161/01.CIR.79.1.8

Frishman, 2008, Cholesteryl ester transfer protein inhibition for coronary heart disease prevention: real hope or despair?, Am J Med, 121, 644, 10.1016/j.amjmed.2008.02.040

Clark, 2004, Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib., Arterioscler Thromb Vasc Biol, 24, 490, 10.1161/01.ATV.0000118278.21719.17

Brousseau, 2004, Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol., N Engl J Med, 350, 1505, 10.1056/NEJMoa031766

Nissen, 2007, Effect of torcetrapib on the progression of coronary atherosclerosis., N Engl J Med, 356, 1304, 10.1056/NEJMoa070635

Kastelein, 2007, Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia., N Engl J Med, 356, 1620, 10.1056/NEJMoa071359

Barter, 2007, Effects of torcetrapib in patients at high risk for coronary events., N Engl J Med, 357, 2109, 10.1056/NEJMoa0706628

Duriez, 2007, The strange case of Dr HDL and Mr HDL: does a NO's story illuminate the mystery of HDL's dark side uncovered by Dr HDL's drug targeting CETP?, Med Hypotheses, 69, 752, 10.1016/j.mehy.2007.01.059

Navab, 1991, Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein., J Clin Invest, 88, 2039, 10.1172/JCI115532

Navab, 2000, Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1., J Lipid Res, 41, 1481, 10.1016/S0022-2275(20)33461-1

Navab, 2008, ApoA-I mimetic peptides as atheroprotective agents in murine models., Curr Drug Targets, 9, 204, 10.2174/138945008783755584

Plump, 1994, Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse., Proc Natl Acad Sci U S A, 91, 9607, 10.1073/pnas.91.20.9607

Chiesa, 2002, Use of recombinant apolipoproteins in vascular diseases: the case of apoA-I., Curr Opin Investig Drugs, 3, 420

Nanjee, 1999, Acute effects of intravenous infusion of apoA1/phosphatidylcholine discs on plasma lipoproteins in humans., Arterioscler Thromb Vasc Biol, 19, 979, 10.1161/01.ATV.19.4.979

Nanjee, 2001, Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans., J Lipid Res, 42, 1586, 10.1016/S0022-2275(20)32212-4

Kujiraoka, 2003, Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on LCAT, PLTP, and CETP in plasma and peripheral lymph in humans., Arterioscler Thromb Vasc Biol, 23, 1653, 10.1161/01.ATV.0000089328.23279.3F

Navab, 2006, Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention., Nat Clin Pract Cardiovasc Med, 3, 540, 10.1038/ncpcardio0661

Getz, 2009, Apoprotein A-I mimetic peptides and their potential anti-atherogenic mechanisms of action., Curr Opin Lipidol, 20, 171, 10.1097/MOL.0b013e32832ac051

Navab, 2006, Potential clinical utility of high-density lipoprotein-mimetic peptides., Curr Opin Lipidol, 17, 440, 10.1097/01.mol.0000236371.27508.d4

Yu, 2008, Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides., Curr Atheroscler Rep, 10, 171, 10.1007/s11883-008-0025-z

Navab, 2007, Peptide mimetics of apolipoproteins improve HDL function., J Clin Lipidol, 1, 142, 10.1016/j.jacl.2007.03.002

Anantharamaiah, 1985, Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine., J Biol Chem, 260, 10248, 10.1016/S0021-9258(17)39238-4

Anantharamaiah, 1986, Synthetic peptide analogs of apolipoproteins., Methods Enzymol, 128, 627, 10.1016/0076-6879(86)28096-9

Datta, 2001, Effects of increasing hydrophobicity on the physical-chemical and biological properties of class A amphipathic helical peptide., J Lipid Res, 25, 1096, 10.1016/S0022-2275(20)31599-6

Navab, 2005, Apolipoprotein A-I mimetic peptides., Arterioscler Thromb Vasc Biol, 25, 1325, 10.1161/01.ATV.0000165694.39518.95

Van Lenten, 2008, Anti-inflammatory apoA-I mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I., J Lipid Res, 49, 2303, 10.1194/jlr.M800075-JLR200

Navab, 2000, Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3., J Lipid Res, 41, 1495, 10.1016/S0022-2275(20)33462-3

Tsimikas, 2005, Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease., N Engl J Med, 353, 46, 10.1056/NEJMoa043175

Navab, 2002, Oral administration of an apoA-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol., Circulation, 105, 290, 10.1161/hc0302.103711

Riley, 2008, Vaccines in development to prevent and treat atherosclerotic disease., Cardiol Rev, 16, 288, 10.1097/CRD.0b013e3181885933

Van Lenten, 2001, High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection., Circulation, 103, 2283, 10.1161/01.CIR.103.18.2283

Van Lenten, 2002, Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein mimetic peptide., Circulation, 106, 1127, 10.1161/01.CIR.0000030182.35880.3E

Van Lenten, 2004, D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes., Circulation, 110, 3252, 10.1161/01.CIR.0000147232.75456.B3

Troutt, 2008, An apolipoprotein A-I mimetic dose-dependently increases the formation of pre-beta1 HDL in human plasma., J Lipid Res, 49, 581, 10.1194/jlr.M700385-JLR200

Navab, 2004, Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice., Circulation, 109, r120, 10.1161/01.CIR.0000134275.90823.87

Navab, 2004, The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL., J Lipid Res, 45, 993, 10.1194/jlr.R400001-JLR200

Li, 2004, Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice., Circulation, 110, 1701, 10.1161/01.CIR.0000142857.79401.69

Navab, 2005, D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice., Arterioscler Thromb Vasc Biol, 25, 1426, 10.1161/01.ATV.0000167412.98221.1a

Ou, 2003, L-4F, an apolipoprotein A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells., Circulation, 107, 1520, 10.1161/01.CIR.0000061949.17174.B6

Ou, 2003, L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease., Circulation, 107, 2337, 10.1161/01.CIR.0000070589.61860.A9

Ou, 2005, Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet., Circ Res, 97, 1190, 10.1161/01.RES.0000190634.60042.cb

Nicholls, 2005, Formation of dysfunctional high-density lipoprotein by myeloperoxidase., Trends Cardiovasc Med, 15, 212, 10.1016/j.tcm.2005.06.004

Navab, 2005, An apolipoprotein A-I mimetic works best in the presence of apolipoprotein A-I., Circ Res, 97, 1085, 10.1161/01.RES.0000194558.86099.ba

Kruger, 2005, D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in a rat model of diabetes., Circulation, 111, 3126, 10.1161/CIRCULATIONAHA.104.517102

Peterson, 2007, Long-term treatment with the apolipoprotein A1 mimetic peptide increases antioxidants and vascular repair in type I diabetic rats., J Pharmacol Exp Ther, 322, 514, 10.1124/jpet.107.119479

Peterson, 2008, L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice., J Lipid Res, 49, 1658, 10.1194/jlr.M800046-JLR200

Peterson, 2009, The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice., J Lipid Res, 50, 1293, 10.1194/jlr.M800610-JLR200

Weihrauch, 2007, Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice., Am J Physiol Heart Circ Physiol, 293, H1432, 10.1152/ajpheart.00038.2007

Araujo, 2003, Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouse., J Immunol, 171, 1572, 10.4049/jimmunol.171.3.1572

Schnickel, 2006, Cytoprotective gene HO-1 and chronic rejection in heart transplantation., Transplant Proc, 38, 3259, 10.1016/j.transproceed.2006.10.156

Buga, 2006, D-4F decreased brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet., J Lipid Res, 47, 2148, 10.1194/jlr.M600214-JLR200

Bajetto, 2002, Characterization of chemokines and their receptors in the central nervous system: physiologic implications., J Neurochem, 82, 1311, 10.1046/j.1471-4159.2002.01091.x

Tran, 2004, Chemokine receptors are expressed widely by embryonic and adult neural progenitor cells., J Neurosci Res, 76, 20, 10.1002/jnr.20001

Buga, 2008, D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet., J Lipid Res, 49, 192, 10.1194/jlr.M700433-JLR200

Bloeden, 2008, Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients., J Lipid Res, 49, 1344, 10.1194/jlr.P800003-JLR200

Duffy, 2005, Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport., Curr Opin Cardiol, 20, 301, 10.1097/01.hco.0000168532.69342.26